Loading...
XNAS
IRIX
Market cap16mUSD
Dec 05, Last price  
0.94USD
1D
1.17%
1Q
-32.84%
Jan 2017
-93.31%
Name

IRIDEX Corp

Chart & Performance

D1W1MN
XNAS:IRIX chart
P/E
P/S
0.33
EPS
Div Yield, %
Shrs. gr., 5y
3.70%
Rev. gr., 5y
2.30%
Revenues
49m
-6.17%
37,029,00035,904,00055,532,00048,528,00043,212,00043,694,00033,159,00033,859,00038,273,00042,814,00041,757,00046,158,00041,593,00042,600,00043,447,00036,347,00053,903,00056,972,00051,869,00048,669,000
Net income
-9m
L-6.90%
1,671,000-5,753,000-22,272,000-7,370,0002,585,0003,046,0002,610,0001,438,0002,231,00010,038,000474,000-11,713,000-12,867,000-12,813,000-8,813,000-6,329,000-5,225,000-7,547,000-9,570,000-8,910,000
CFO
-7m
L+8.01%
2,770,000-1,385,000-522,000-96,0006,798,0003,479,0003,048,000-443,000767,0004,014,000-593,000-144,000-3,565,000-10,025,000-7,913,000-3,237,0008,217,000-9,519,000-6,745,000-7,285,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
IPO date
Feb 16, 1996
Employees
130
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122022‑002021‑002019‑122018‑122017‑122016‑122016‑00
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT